Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06984510

Enrollment

2720

Registered

2025-05-22

Start date

2025-04-01

Completion date

2025-12-31

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biological Age, Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes Mellitus (T2DM)

Brief summary

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Interventions

OTHERObservational

Observational

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Inclusion criteria

1. Abdominal ultrasound data available in annual health check-up records 2. At least one of the following five metabolic indicators recorded annually: (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)

Exclusion criteria

1. Age \<20 or \>90 years 2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection) 3. Type 2 diabetes mellitus at baseline 4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Design outcomes

Primary

Measure	Time frame
Incidence of onset T2DM	through study completion, an average of 3 year

Countries

China

Contacts

Primary ContactLei Xu

xulei22@163.com+8613486659126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026